secwatch / observer
PYXS Pyxis Oncology, Inc.
CIK 0001782223 50 ready 8-Ks latest August 13, 2026, 7:42 AM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)
Ready 8-Ks 50
Latest filing August 13, 2026, 7:42 AM ET
Top materiality 0.85
Event mix earnings ×16 · other_material ×13 · leadership ×8
Sentiment 13 pos · 0 neg · 37 neu
Latest earnings reported 2026-Q2
Executive change recent →

Recent 8-K filings for PYXS

Highest-materiality recent filing

Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC

December 18, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

Read filing →

Executive changes

Departed

Lara Sullivan

Director
PYXS · Pyxis Oncology, Inc.
Effective
2026-04-29
Filed
April 30, 2026, 7:59 PM ET
Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.
Departed

Lara Sullivan

Chief Executive Officer
PYXS · Pyxis Oncology, Inc.
Effective
2026-04-29
Filed
April 30, 2026, 7:59 PM ET
On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.
Role change

Lara S. Sullivan

Chief Medical Officer
PYXS · Pyxis Oncology, Inc.
Effective
2025-03-18
Filed
March 18, 2025, 7:59 PM ET
Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.
Departed

Ken Kobayashi

Chief Medical Officer
PYXS · Pyxis Oncology, Inc.
Effective
2025-03-18
Successor
Lara S. Sullivan
Filed
March 18, 2025, 7:59 PM ET
On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.
Appointed

Michael A. Metzger

Director
PYXS · Pyxis Oncology, Inc.
Effective
2024-06-10
Filed
June 10, 2024, 7:59 PM ET
On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).
Appointed

Santhosh Palani, Ph.D., CFA

Director
PYXS · Pyxis Oncology, Inc.
Effective
2024-03-12
Filed
March 13, 2024, 7:59 PM ET
On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).
Appointed

Ken Kobayashi

Chief Medical Officer
PYXS · Pyxis Oncology, Inc.
Effective
2023-11-27
Filed
November 28, 2023, 6:59 PM ET
On November 28, 2023, Pyxis Oncology, Inc. (the “Company”) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the “Effective Date”).
Appointed

Jakob Dupont

Director
PYXS · Pyxis Oncology, Inc.
Effective
2023-08-23
Filed
August 23, 2023, 7:59 PM ET
On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.
Appointed

Jakob Dupont

Director
PYXS · Pyxis Oncology, Inc.
Filed
June 30, 2023, 7:59 PM ET
the Board also approved on a prospective basis the appointment of Jakob Dupont, M.D. as a director of the Company to fill the vacancy created by that action.
Departed

Jay Feingold

Chief Medical Officer
PYXS · Pyxis Oncology, Inc.
Effective
2023-06-15
Filed
May 24, 2023, 7:59 PM ET
On May 24, 2023, the Company announced that Jay Feingold, M.D., Ph.D., will be stepping down from his position as the Company's Chief Medical Officer to pursue other opportunities.
Role change

Pamela Connealy

Chief Financial Officer and Chief Operating Officer
PYXS · Pyxis Oncology, Inc.
Effective
2023-03-22
Filed
March 22, 2023, 7:59 PM ET
On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.
Appointed

Rachel Humphrey

Director
PYXS · Pyxis Oncology, Inc.
Effective
2022-08-11
Filed
August 15, 2022, 7:59 PM ET
On August 11, 2022, Pyxis Oncology, Inc. appointed Rachel Humphrey, M.D., to its Board of Directors and to serve on the Board’s Nominating and Corporate Governance Committee and Compensation Committee.

Earnings & guidance

2026-Q2 EPS reported -$0.76 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

13 positive 0 negative 37 neutral

source · PYXS on sec.gov